Amgen (AMGN) has been featured heavily across the financial spectrum, with various moves by numerous investment management firms. AGF Management Ltd, Sequoia Financial Advisors LLC, Saturna Capital Corp, and Pzena Investment Management LLC, among others, all have adjusted their holdings in the leading biotechnology company. The company has recently announced promising MINT trial data for
Uplizna, its medication for Myasthenia Gravis, and also reported successful top-line results from
ROCATINLIMAB phase 3 for Atopic Dermatitis. The highlight, however, was the groundbreaking strides in their upcoming filings, with Uplizna impressing in gMG. The company has also announced its
second-quarter dividend for the year 2025 and released fourth-quarter and full-year 2024 financial results showing steady gains for seven consecutive sessions. Amgen has also been involved in several late-stage studies, including one on eczema. The company's ongoing clinical trials for a
weight-loss drug have also attracted much attention to the stock. While they continue to ride the tide of monthly weight loss results, R&D Chief is expected to indicate new breakthroughs at an upcoming Healthcare Conference.
Amgen AMGN News Analytics from Mon, 06 Jan 2025 08:00:00 GMT to Sat, 15 Mar 2025 23:12:47 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -3
